vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($220.8M vs $205.4M, roughly 1.1× COLLEGIUM PHARMACEUTICAL, INC). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs 5.8%, a 2.4% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 9.6%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $-19.2M). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs 9.5%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
COLL vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $220.8M |
| Net Profit | $17.0M | $12.8M |
| Gross Margin | 62.5% | — |
| Operating Margin | 29.6% | 7.1% |
| Net Margin | 8.3% | 5.8% |
| Revenue YoY | 12.9% | 9.6% |
| Net Profit YoY | 35.3% | -42.1% |
| EPS (diluted) | $0.48 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | $220.8M | ||
| Q3 25 | $209.4M | $222.4M | ||
| Q2 25 | $188.0M | $204.3M | ||
| Q1 25 | $177.8M | $207.4M | ||
| Q4 24 | $181.9M | $201.4M | ||
| Q3 24 | $159.3M | $196.4M | ||
| Q2 24 | $145.3M | $177.5M | ||
| Q1 24 | $144.9M | $184.2M |
| Q4 25 | $17.0M | $12.8M | ||
| Q3 25 | $31.5M | $18.8M | ||
| Q2 25 | $12.0M | $10.7M | ||
| Q1 25 | $2.4M | $11.4M | ||
| Q4 24 | $12.5M | $22.2M | ||
| Q3 24 | $9.3M | $18.8M | ||
| Q2 24 | $19.6M | $5.0M | ||
| Q1 24 | $27.7M | $7.8M |
| Q4 25 | 62.5% | — | ||
| Q3 25 | 61.7% | — | ||
| Q2 25 | 57.7% | — | ||
| Q1 25 | 54.8% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 62.5% | — | ||
| Q1 24 | 63.1% | — |
| Q4 25 | 29.6% | 7.1% | ||
| Q3 25 | 29.7% | 11.2% | ||
| Q2 25 | 18.7% | 6.9% | ||
| Q1 25 | 12.2% | 8.1% | ||
| Q4 24 | 20.9% | 13.6% | ||
| Q3 24 | 21.9% | 13.3% | ||
| Q2 24 | 32.7% | 4.2% | ||
| Q1 24 | 34.1% | 6.1% |
| Q4 25 | 8.3% | 5.8% | ||
| Q3 25 | 15.0% | 8.4% | ||
| Q2 25 | 6.4% | 5.2% | ||
| Q1 25 | 1.4% | 5.5% | ||
| Q4 24 | 6.9% | 11.0% | ||
| Q3 24 | 5.9% | 9.6% | ||
| Q2 24 | 13.5% | 2.8% | ||
| Q1 24 | 19.1% | 4.2% |
| Q4 25 | $0.48 | $0.23 | ||
| Q3 25 | $0.84 | $0.33 | ||
| Q2 25 | $0.34 | $0.19 | ||
| Q1 25 | $0.07 | $0.21 | ||
| Q4 24 | $0.36 | $0.40 | ||
| Q3 24 | $0.27 | $0.35 | ||
| Q2 24 | $0.52 | $0.09 | ||
| Q1 24 | $0.71 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $162.8M |
| Total DebtLower is stronger | — | $101.4M |
| Stockholders' EquityBook value | $301.7M | $335.9M |
| Total Assets | $1.7B | $834.0M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | $162.8M | ||
| Q3 25 | $285.9M | $169.1M | ||
| Q2 25 | $222.2M | $70.7M | ||
| Q1 25 | $197.8M | $96.0M | ||
| Q4 24 | $162.8M | $172.0M | ||
| Q3 24 | $120.0M | $161.9M | ||
| Q2 24 | $271.6M | $115.5M | ||
| Q1 24 | $318.0M | $116.1M |
| Q4 25 | — | $101.4M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $94.4M | ||
| Q4 24 | — | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M | ||
| Q1 24 | — | $141.9M |
| Q4 25 | $301.7M | $335.9M | ||
| Q3 25 | $274.8M | $328.1M | ||
| Q2 25 | $232.2M | $306.8M | ||
| Q1 25 | $234.4M | $293.9M | ||
| Q4 24 | $228.8M | $280.0M | ||
| Q3 24 | $234.3M | $260.2M | ||
| Q2 24 | $216.6M | $239.4M | ||
| Q1 24 | $222.2M | $232.6M |
| Q4 25 | $1.7B | $834.0M | ||
| Q3 25 | $1.6B | $826.1M | ||
| Q2 25 | $1.6B | $740.8M | ||
| Q1 25 | $1.6B | $720.4M | ||
| Q4 24 | $1.7B | $753.8M | ||
| Q3 24 | $1.6B | $744.6M | ||
| Q2 24 | $1.1B | $706.0M | ||
| Q1 24 | $1.1B | $702.1M |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× | ||
| Q1 24 | — | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $3.1M |
| Free Cash FlowOCF − Capex | $122.4M | $-19.2M |
| FCF MarginFCF / Revenue | 59.6% | -8.7% |
| Capex IntensityCapex / Revenue | 0.3% | 10.1% |
| Cash ConversionOCF / Net Profit | 7.25× | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $16.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | $3.1M | ||
| Q3 25 | $78.4M | $57.1M | ||
| Q2 25 | $72.4M | $18.1M | ||
| Q1 25 | $55.4M | $-789.0K | ||
| Q4 24 | $84.6M | $23.0M | ||
| Q3 24 | $-9.0M | $67.5M | ||
| Q2 24 | $67.4M | $10.0M | ||
| Q1 24 | $61.9M | $-2.5M |
| Q4 25 | $122.4M | $-19.2M | ||
| Q3 25 | $78.3M | $40.6M | ||
| Q2 25 | $72.4M | $6.8M | ||
| Q1 25 | $54.6M | $-11.7M | ||
| Q4 24 | $84.1M | $19.6M | ||
| Q3 24 | $-9.2M | $60.0M | ||
| Q2 24 | $67.1M | $3.0M | ||
| Q1 24 | $61.4M | $-8.4M |
| Q4 25 | 59.6% | -8.7% | ||
| Q3 25 | 37.4% | 18.3% | ||
| Q2 25 | 38.5% | 3.4% | ||
| Q1 25 | 30.7% | -5.7% | ||
| Q4 24 | 46.2% | 9.7% | ||
| Q3 24 | -5.8% | 30.6% | ||
| Q2 24 | 46.2% | 1.7% | ||
| Q1 24 | 42.3% | -4.6% |
| Q4 25 | 0.3% | 10.1% | ||
| Q3 25 | 0.1% | 7.4% | ||
| Q2 25 | 0.0% | 5.5% | ||
| Q1 25 | 0.4% | 5.3% | ||
| Q4 24 | 0.3% | 1.7% | ||
| Q3 24 | 0.2% | 3.8% | ||
| Q2 24 | 0.2% | 4.0% | ||
| Q1 24 | 0.4% | 3.2% |
| Q4 25 | 7.25× | 0.24× | ||
| Q3 25 | 2.49× | 3.04× | ||
| Q2 25 | 6.05× | 1.69× | ||
| Q1 25 | 22.92× | -0.07× | ||
| Q4 24 | 6.75× | 1.04× | ||
| Q3 24 | -0.96× | 3.58× | ||
| Q2 24 | 3.44× | 2.01× | ||
| Q1 24 | 2.23× | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COLL
Segment breakdown not available.
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
